Private oncology outfit Oncternal uses GTx as shell to make Nasdaq debut
Months after declaring it was exploring strategic options following the failure of its lead experimental drug in a mid-stage study involving patients with stress …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
